Shire given nod by US for binge-eating disorder drug Vyvanse February 2, 2015 Drugs giant Shire traded up to three per cent higher yesterday morning and closed 0.95 per cent up, after news that the US Food and Drug Administration on Friday approved its new binge-eating disorder drug. Vyvanse, which is currently approved to treat attention deficit hyperactivity disorder, generated sales of more than $1bn (£665m) in the [...]
Shire’s NPS deal validated as US approves drugs January 26, 2015 SHIRE’S $5.2bn (£3.45bn) takeover of NPS Pharmaceuticals just weeks ago is already paying off. Shire shares rose 1.08 per cent yesterday after NPS’s Natpara drug was approved by US regulators over the weekend. The US Food and Drug Administration (FDA) approved Natpara to treat a rare hormone disorder, hypoparathyroidism. Analysts expect the drug to generate [...]
Shire splashes out AbbVie cash with $5.2bn acquisition of NPS Pharma January 12, 2015 UK drugmaker Shire bounced back from its botched takeover by pharma giant AbbVie last night to seal a $5.2bn acquisition of US firm NPS Pharma – using its multi-billion dollar breakup fee from AbbVie to help fund the spending spree. Shire has agreed to buy the US listed biotech firm for $46 a share – [...]
Shire to acquire NPS Pharma in $5.2bn merger January 11, 2015 UK company Shire is to aquire with NPS Pharmaceuticals, according to a statement by the companies. The two have entered into a merger agreement, with Shire buying all outstanding NPS shares for $46 (£30.48) each, with the total said to be at $5.2bn. According to the statement, Shire will look to accelerate NPS Pharma’s innovative [...]
Shire share price soars as it raises full year guidance to “high 30 pc” October 24, 2014 Shire's share price soared this afternoon after the British pharma group posted strong quarterly results, increasing its full year guidance to “the high 30 per cent range”. The group, which acquired ViroPharma in January of this year, reported total revenue growth of 32 per cent for the three months to September 30, reaching $1.6bn [...]
AbbVie blames “outdated” US tax law for Shire deal collapse October 21, 2014 The boss of US drugs giant AbbVie hit out at the “outdated” US tax regime after confirming the $55bn (£34bn) takeover of Shire had collapsed. Chief executive Richard Gonzalez led the charge to buy Dublin drugmaker Shire for three months, only to walk away from the deal last week blaming changes to the US tax [...]
Shire-AbbVie takeover off as James Bowling quits October 20, 2014 Shire last night confirmed its $54bn (£32bn) deal with AbbVie was off, with a $1.635bn break fee owed. In a statement, the Dublin-based pharmaceuticals company said: “In light of the AbbVie Board’s decision to change its recommendation and to advise its shareholders to vote against its Offer, Shire believes that there is now no realistic [...]
Shire eyes deals using $1.6bn AbbVie windfall after takeover bid falls apart October 19, 2014 UK drugmaker Shire is eyeing up a number of acquisitions as it looks set to receive a windfall of as much as $1.6bn (£994m) from AbbVie, as the US pharma giant’s $54bn takeover bid falls apart. Shire is in discussions with acquisition targets including NPS Pharmaceuticals and biopharmaceutical firm Cubist, according to The Sunday Times. [...]
Shire share price falls as AbbVie confirms acquisition is off the table October 16, 2014 Drug-maker Shire saw its share price tumble by a further 10 per cent yesterday, after US company AbbVie confirmed that it had abandoned plans for a $54bn (£32m) acquisition of the firm. Earlier this week, Shire said that it would be owed “a break fee of approximately $1.64bn” if AbbVie shareholders voted against the offer. [...]
Shire share price falls again as AbbVie board recommends shareholders reject takeover bid October 16, 2014 The billion-pound deal between AbbVie and Shire could be over. AbbVie has recommended shareholders vote against the proposed $54bn (£32bn) deal to buy UK drugmaker Shire, essentially ending the takeover bid and sending Shire shares down an initial 12 per cent when markets opened this morning. The US pharmaceutical firm AbbVie said it was rethinking the [...]